| Symbol | EOLS |
|---|---|
| Name | EVOLUS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 520 NEWPORT CENTER DRIVE,SUITE 1200, NEWPORT BEACH, California, 92660, United States |
| Telephone | +1 949 - 284-4555 |
| Fax | — |
| — | |
| Website | https://www.evolus.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001570562 |
| Description | Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The companys first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. Additional info from NASDAQ: |
Evolus - Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Read moreEvolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Read moreEvolus - Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Read moreEvolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Read moreEvolus - Evolus to Report Second Quarter Financial Results on August 5, 2026
Read moreEvolus - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreEvolus - Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Read moreNew Form EFFECT - Evolus, Inc. <b>Filed:</b> 2026-06-12 <b>AccNo:</b> 9999999995-26-001986 <b>Size:</b> 1 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06604832 | Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture | Phase1 | Skin Aging | Completed | 2024-09-03 | 2025-09-16 | ClinicalTrials.gov |
| NCT05807412 | Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of… | Early_Phase1 | Rhytides | Completed | 2023-05-01 | 2024-02-26 | ClinicalTrials.gov |
| NCT05481931 | Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Sev… | — | Glabellar Frown Lines | Completed | 2023-03-15 | 2026-04-13 | ClinicalTrials.gov |
| NCT05320393 | Study to Demonstrate Safety and Duration of Effect of 40 Units of Prabotulinumt… | Phase2 | Glabellar Frown Lines | Completed | 2022-03-30 | 2023-05-22 | ClinicalTrials.gov |
| NCT05129319 | Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD | Early_Phase1 | Glabellar Frown Lines | Completed | 2021-12-16 | 2023-06-15 | ClinicalTrials.gov |
| NCT02428608 | Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV… | Phase2 | Glabellar Frown Lines | Completed | 2015-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02334423 | A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Gl… | Phase3 | Glabellar Frown Lines | Completed | 2015-01-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02334436 | A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Gl… | Phase3 | Glabellar Frown Lines | Completed | 2015-01-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02184988 | Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Tr… | Phase2 | Glabellar Frown Lines | Completed | 2014-08-01 | 2015-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | COMPLETED | NCT05481931 |
| 0.9% sterile, unpreserved saline | Other | Phase PHASE3 | Glabellar Frown Lines | COMPLETED | NCT02334436 |
| Botulinum toxin, Type A | Other | Phase PHASE3 | Glabellar Frown Lines | COMPLETED | NCT02334436 |
| 0.9% sterile, unpreserved saline | Other | Phase PHASE3 | Glabellar Frown Lines | COMPLETED | NCT02334423 |
| Botulinum toxin, Type A | Other | Phase PHASE3 | Glabellar Frown Lines | COMPLETED | NCT02334423 |
| DWP-450 (Botulinum purified neurotoxin, Type A) | Other | Phase PHASE2 | Glabellar Frown Lines | COMPLETED | NCT02428608 |
| Botulinum purified neurotoxin, Type A | Other | Phase PHASE2 | Glabellar Frown Lines | COMPLETED | NCT02184988 |
| prabotulinumtoxinA | Other | Phase EARLY_PHASE1 | Glabellar Frown Lines | COMPLETED | NCT05129319 |
| OnabotulinumtoxinA | Other | Phase EARLY_PHASE1 | Rhytides | COMPLETED | NCT05807412 |
| PrabotulinumtoxinA-Xvfs | Other | Phase EARLY_PHASE1 | Rhytides | COMPLETED | NCT05807412 |
| OnabotulinumtoxinA | Other | Phase PHASE2 | Glabellar Frown Lines | COMPLETED | NCT05320393 |
| PrabotulinumtoxinA-Xvfs | Other | Phase PHASE2 | Glabellar Frown Lines | COMPLETED | NCT05320393 |
| prabotulinumtoxinA | Other | Preclinical | Glabellar Frown Lines | ACTIVE_NOT_RECRUITING | NCT05481931 |
| saline solution (placebo) | Other | Phase PHASE1 | Skin Aging | COMPLETED | NCT06604832 |
| IncobotulinumtoxinA | Other | Phase PHASE1 | Skin Aging | COMPLETED | NCT06604832 |
| PrabotulinumtoxinA-Xvfs | Other | Phase PHASE1 | Skin Aging | COMPLETED | NCT06604832 |
| saline solution (placebo) | DRUG | Phase PHASE1 | Skin Aging | COMPLETED | NCT06604832 |
| IncobotulinumtoxinA | DRUG | Phase PHASE1 | Skin Aging | COMPLETED | NCT06604832 |
| OnabotulinumtoxinA | DRUG | Phase EARLY_PHASE1 | Rhytides | COMPLETED | NCT05807412 |
| PrabotulinumtoxinA-Xvfs | DRUG | Phase PHASE1 | Skin Aging | COMPLETED | NCT06604832 |
| prabotulinumtoxinA | DRUG | Preclinical | Glabellar Frown Lines | ACTIVE_NOT_RECRUITING | NCT05481931 |
| DWP-450 (Botulinum purified neurotoxin, Type A) | BIOLOGICAL | Phase PHASE2 | Glabellar Frown Lines | COMPLETED | NCT02428608 |
| 0.9% sterile, unpreserved saline | OTHER | Phase PHASE3 | Glabellar Frown Lines | COMPLETED | NCT02334436 |
| Botulinum toxin, Type A | BIOLOGICAL | Phase PHASE3 | Glabellar Frown Lines | COMPLETED | NCT02334436 |
| Botulinum purified neurotoxin, Type A | BIOLOGICAL | Phase PHASE2 | Glabellar Frown Lines | COMPLETED | NCT02184988 |